EQ vs TRAX
EQ: A clinical-stage biotechnology company developing novel aryl hydrocarbon receptor (AhR) modulators for autoimmune and inflammatory diseases. TRAX: Clinical-stage antibody-focused biotech advancing immune-modulating therapies for autoimmune and inflammatory diseases including celiac disease, eosinophilic esophagitis, and rheumatoid arthritis.
Side-by-side fundamentals
| Metric | EQ | TRAX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.76 | $38.17 | |
| Market cap as of 2026-07-23 | $174M | $1.3B | |
| Net margin as of 2026-07-23 | -19.6% | n/a | |
| Operating margin as of 2026-07-23 | -20.1% | n/a | |
| ROE as of 2026-07-23 | -61.4% | -57.8% | TRAX higher |
| ROA as of 2026-07-23 | -53.7% | -50.2% | TRAX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue CAGR (3y) SEC XBRL | +61.5% | n/a | |
| Beta as of 2026-07-23 | 1.85 | 1.19 | |
| 1-year return as of 2026-07-22 close | +541.5% | +100.9% | EQ higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.